Ribose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Ribose
Accession Number
DB15073
Type
Small Molecule
Groups
Investigational
Description

Ribose is under investigation in clinical trial NCT01727479 (Ribose and Sport Performance).

Structure
Thumb
Synonyms
  • D-Ribose
  • RIBOSE
Categories
UNII
681HV46001
CAS number
50-69-1
Weight
Average: 150.1299
Monoisotopic: 150.05282343
Chemical Formula
C5H10O5
InChI Key
PYMYPHUHKUWMLA-LMVFSUKVSA-N
InChI
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5-/m0/s1
IUPAC Name
(2R,3R,4R)-2,3,4,5-tetrahydroxypentanal
SMILES
OC[C@@H](O)[C@@H](O)[C@@H](O)C=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4470639
ChEBI
47014
HET
RB5
Wikipedia
Ribose
PDB Entries
3ph3 / 6nch / 6nci

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentProstate Cancer1
1RecruitingTreatmentBreast Neoplasm Malignant Female / Breast Neoplasms, Triple-Negative / Radiotherapy Side Effect1
1, 2TerminatedTreatmentTumors, Solid1
2CompletedTreatment5'-Nucleotidase Syndrome1
2CompletedTreatmentFibromyalgia1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Locally Advance Pancreatic Ductal Adenocarcinoma / Locally Advanced Malignant Solid Neoplasm / Locally Advanced Pancreatic Cancer / Metastatic Malignant Solid Neoplasm / Metastatic Renal Cell Carcinoma / Pancreatic Cancer Metastatic / Pancreatic Ductal Adenocarcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v8 / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v8 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v8 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC v8 / Urothelial carcinoma ureter metastatic1
2RecruitingTreatmentHeart Failure, Diastolic1
2WithdrawnTreatmentCongestive Heart Failure1
Not AvailableTerminatedNot AvailableCongestive Heart Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility380.0 mg/mLALOGPS
logP-2.3ALOGPS
logP-2.9ChemAxon
logS0.4ALOGPS
pKa (Strongest Acidic)12.34ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity31.38 m3·mol-1ChemAxon
Polarizability13.39 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 MEOX; 4 TMS)GC-MSsplash10-0udi-1920000000-2a376699e06455c76ff7
GC-MS Spectrum - GC-MS (1 MEOX; 4 TMS)GC-MSsplash10-0uxr-0941000000-7b9d79f55ddb22a39810
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:47 / Updated on November 02, 2019 03:29